A new contained human immunodeficiency virus type 1 host cell system for evaluation of antiviral activities of interferons and other agents in vitro
HIV-host infection systems in vitro are important in the pre-clinical assessment of anti-retroviral drug activity. The present report describes the development of a new HIV-host model comprised of an epithelial cell line of HeLa lineage (HeLa-1), transfected with expression vectors bearing tat and r...
Gespeichert in:
Veröffentlicht in: | Antiviral research 1999-07, Vol.42 (3), p.177-187 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | HIV-host infection systems in vitro are important in the pre-clinical assessment of anti-retroviral drug activity. The present report describes the development of a new HIV-host model comprised of an epithelial cell line of HeLa lineage (HeLa-1), transfected with expression vectors bearing
tat and
rev (TART) genes of HIV-1 as well as the CD4 receptor gene, and HIV-1
ΔTat/Rev, a biologically contained strain of HIV-1 deleted in
tat and
rev. Measurement of infectivity, by syncytium formation and reverse transcriptase assay, revealed that HeLa-1 is infected with HIV-1
ΔTat/Rev. This virus failed to productively infect the TART-deficient CD4-positive HeLa cells, confirming its contained, non-infectious nature. The HeLa-1/HIV-1
ΔTat/Rev system was used to measure the anti-retroviral activity of a human leukocyte-derived interferon (IFN-αn3) preparation, several nucleoside analogs, and protease inhibitors. The HeLa-1/HIV-1
ΔTat/Rev model provides a biologically contained system for the study of the HIV pathogenesis and the relative and combined therapeutic effects of anti-retroviral agents in vitro. |
---|---|
ISSN: | 0166-3542 1872-9096 |
DOI: | 10.1016/S0166-3542(99)00014-5 |